


응용 자료

Fast and Automatic Mapping of Disulfide Bonds in a Monoclonal Antibody using SYNAPT G2 HDMS and BiopharmaLynx 1.3

Hongwei Xie, Weibin Chen

Waters Corporation



Abstract

In this study, an advanced LC-MS^E peptide mapping workflow is demonstrated for the detection and identification of disulfide linkages, including scrambled disulfide linkages, in a recombinant IgG1 mAb. We develop a viable, integrated approach for automatic mapping or monitoring of disulfide bonded peptides in a protein with multiple cysteines.

Benefits

- Detection and identification of disulfide linkages, including scrambled disulfide linkages, in a recombinant IgG1 mAb
- Develop a viable, integrated approach for automatic mapping or monitoring of disulfide bonded peptides in a protein with multiple cysteines.

Introduction

Disulfide bond formation is critical for establishing and maintaining proper three-dimensional folding and therefore functions of therapeutic proteins, e.g., monoclonal antibodies (mAbs). Localization and assignment of disulfide bonds are an important aspect of protein structural analysis.

However, the identification of disulfide pairing in a protein with multiple cysteine residues is generally more time-consuming and challenging than the determination of the protein sequence due to incomplete disulfide bond formation and disulfide bond scrambling.^{1,2}

The combination of enzymatic digestion with liquid chromatography-mass spectrometry (LC-MS) is frequently applied as a routine method for the assignment of disulfide bonds.^{3,4} However, peptide mapping via an LC-MS approach is traditionally labor-intensive and time-consuming in data processing and interpretation.

Furthermore, the assignment of disulfide linkages sometime is inconclusive when a protein contains multiple cysteines due to the significantly increased number of possible disulfide-bonded peptide isomers.¹ For example, there are totally 105 possible disulfide-bond pairing schemes for a protein containing eight cysteine residues (while an IgG1 mAb typically has 32 or more cysteines in its two light chains and two heavy

chains).

This, plus the reality of potential disulfide bond scrambling, makes the disulfide bond assignment extremely difficult when the analysis is performed manually. An automated workflow is highly preferred for quick assessment of heterogeneities of therapeutic proteins caused by the disulfide linkages.

Recently, we have developed an integrated peptide mapping workflow for protein sequence confirmation and characterization using a UPLC-MS^E method for data collection and a targeted bioinformatic tool, the BiopharmaLynx Application Manager for MassLynx Software, for automated data processing and annotation.

5

The data independent MS^E approach alternatively collects mass spectrometric data of precursors and fragments of eluting peptides from protein enzymatic (e.g., tryptic) digests in an unbiased manner.⁶ The integrated workflow overcomes most shortcomings of traditional peptide mapping methods⁷ and has been demonstrated to be fast, robust and suitable for routine analysis of recombinant proteins such as therapeutic mAbs⁵ and subunit vaccines.⁸ The approach has also been successfully applied to identify expected disulfide bonds in an IgG1 mAb.⁹

In this study, an advanced UPLC-MS^E peptide mapping workflow is demonstrated for the detection and identification of disulfide linkages (including scrambled disulfide linkages) in a recombinant IgG1 mAb. The goal is to develop a viable approach for automatic mapping or monitoring of disulfide bonded peptides in a protein with multiple cysteines.

The significances of the integrated workflow include:

- Enhanced mass resolution and mass accuracy using the SYNAPT HDMS G2 QToF MS System,¹⁰ which is critical for acquiring high-quality MS^E data for large disulfide-bond-linked peptides with high molecular weight.
- Automatic assignment of disulfide linkages by an upgraded BiopharmaLynx (version 1.3) in a randomized mode, which is important for the identification of potential scrambled disulfide bonds in an automatic mode.

To reduce the complexity of protein digest mixture, the mAb was digested with endoproteinase Lys-C. The obtained digests were separated by reversed-phase LC with an ACQUITY UPLC System, followed by online MS^E detection and BiopharmaLynx 1.3 analysis. Digests prepared with and without alkylation protection of free sulfhydryl groups² in the sample were used to differentiate native scrambled disulfide linkages in the mAb from those potentially formed during sample preparation stage.

Experimental

LC conditions

LC system:	ACQUITY UPLC
Column:	ACQUITY UPLC BEH300 C4, 1.7 μm , 2.1 x 150 mm (p/n 186004497) or ACQUITY UPLC BEH300 C ₁₈ , 1.7 μm , 2.1 x 150 mm (p/n 186003687)
Column temp.:	65 °C
Flow rate:	200 $\mu\text{L}/\text{min}$
Injection vol.:	5 μL (partial loop injection mode)
Mobile phase A:	0.1% FA in water
Mobile phase B:	0.1% FA in ACN
Gradient:	1–40% in 90 min

MS conditions

MS system:	SYNAPT HDMS G2
Ionization mode:	ESI+
Acquisition mode:	MS ^E
Low collision energy:	4 eV

Elevated collision energy:	Ramping from 22 to 48 eV
Capillary voltage:	3.0 kV
Cone voltage:	30 V
Scan mode:	Resolution mode (resolution ≥ 20000)
Scan time:	0.5 second
Source temp.:	100 °C
Desolvation temp.:	350 °C
Mass range:	100 to 2500 Da
Mass accuracy:	Lockmassed by GFP sprayed from lockmass channel every 30 seconds

Data management

BiopharmaLynx 1.3 Application Manager for MassLynx Software

Materials and reagents

Endoproteinase Lys-C (Wako) and iodoacetamide (Sigma) were used along with *Rapi*Gest (Waters, p/n 186001861). The IgG1 mAb Trastuzumab digests were prepared by incubating the sample (protein/Lys-C of 50:1) in 50 mM tris buffer (pH ~7.5) at 37 °C and the presence of 0.1% *Rapi*Gest SF for 18 hours. Prior to digestion, the protein was denatured at 80 °C for 10 min. For testing artificial scrambling potentially introduced during digestion, a digest prepared without alkylation was directly compared with a digest prepared in parallel with IAM alkylation before the digestion.

Results and Discussion

Like all IgG1 mAbs, the Trastuzumab antibody should have nine unique disulfide bonds when formed properly. *In-silico* digestion (by Lys-Cp) shows that eight expected disulfide linked peptides (or unique linkages) are generated after digestion, including two in each of light chain, four in each of heavy chain, one between light chain and heavy chain, and one between the two heavy chains (which has two disulfide bonds connecting with).

To demonstrate that the workflow works properly to identify the formed disulfide linkages, the collected LC-MS^E data were first searched against the mAb sequences with properly linked cysteines to form the 16 expected disulfide bonds in the BiopharmaLynx method setting.

Figure 1 shows the determination of the largest disulfide linkages 1:K1–1:K4 (an intra disulfide linkage of light chain, monoisotopic mass 10657.12 Da). The disulfide-bonded peptide was detected and annotated based on the precursor mass MH⁺ (Figure 1C) that was obtained from multiply-charged, isotope resolved raw MS data (Figure 1B). The assignment was also confirmed by elevated-energy fragmentation MS^E spectrum (also charge-reduced, isotope-deconvoluted to singly-charged ions, as shown in Figure 1D) upon the retention time-alignment (as highlighted in Figure 1A). The MS^E spectrum not only contains b/y ions from the two individual peptides (1:K1 and 1:K4), but also has ions corresponding to disulfide-bonded fragments from both peptides such as 7019.27 Da (1/y39–2/y24) and 10431.19 Da (1/y39–2/y56), providing unequivocal evidences for the disulfide linkage.

because proteases such as Lys-C or trypsin tend to miss the cleavage site when a lysine (K) is followed by a proline (P) residue.




Figure 2. Identification and confirmation of disulfide linkages 2:K7-2:K8 and 2:K7-2:K8-9. A) BiopharmaLynx interpretation and annotation; B) MS^E spectrum of 2:K7-2:k8; C) MS^E spectrum of 2:K7-2:K8-9.

It is observed that high percentage of organic solvent (10% or more acetonitrile) is needed in the sample to help maintain the solubility of large disulfide-bonded peptides during LC-MS analysis. One disadvantage of the use of high organic in sample buffer is that this could result in the elution of the smallest disulfide-bonded peptides 1:K14-2:K13 (SFNRGEC=SCDK) in void volume.

One challenge in disulfide bond mapping is to identify those peptides formed unexpectedly, e.g., due to scrambling. Therefore, the processing method was next created for Scrambled Disulfides (see the highlight part in Figure 3), which allows for detection and identification of all possible disulfide pairing formed between any two cysteines in the mAb. Lys-C digests of Trastuzumab with or without alkylation prior to digestion were analyzed for this investigation.




Figure 3. A screen capture showing the Scrambled Disulfides function in BiopharmaLynx 1.3 data processing method setting.

Using this new method, not only the expected disulfide linkages were identified, some minor scrambled disulfide linkages were also detected. Figure 4A illustrates three identified scrambled disulfide linkages (1:K13–2:K16, 1:K7–2:K21, 1:K14–2:K16) in the digest without alkylation. Again, elevated-energy fragmentation (MS^E) data were available for confirmation of the assignments (the MS^E spectrum of 1:K13–2:K16 is plotted in Figure 4B as an example).




Figure 4. Examples of identified scrambled disulfide linkages with automatic interpretation and annotation. A) BiopharmaLynx interpretation and annotation; B) MS^E spectrum of scrambled disulfide linkage 1:K13-2:K16.

The scrambled 1:K13-2:K16 and 1:K14-2:K16 were only identified from the digest without alkylation and not detected in the digest with alkylation, suggesting these were artifacts introduced by sample preparation. The scrambled disulfide linkage 1:K7-2:K21 was identified in both digests (with or without alkylation), however, its abundance is much lower in the alkylated sample compared to the non-alkylated one (see the inset in Figure 4A). As expected, all the identified scrambled disulfide linkages are minor compared to the expected disulfide linkages (as illustrated in Figure 4A).

The successful determination of both expected and scrambled disulfide linkages demonstrated that the integrated workflow is capable of automatically mapping disulfide linkages in a protein. The enhanced function of Scrambled Disulfides requires no manual efforts, and achieves completely automatic data processing for the challenging task of disulfide bond mapping.

Conclusion

An integrated workflow, combining high mass resolution UPLC/MS^E with BiopharmaLynx 1.3, was developed for rapid mapping of disulfide linkages in a recombinant IgG1 mAb. The workflow was demonstrated to be capable of simultaneous identification of both expected and scrambled disulfide linked peptides. Assignment of disulfide bond linked peptides is automated, based on accurate MS measurement and confirmed by elevated collision energy MS^E fragmentation data.

The improved mass resolution – 20,000 for resolution mode and 40,000 for high-resolution mode – offered by the SYNAPT G2 HDMS System greatly enhances the MS data quality for large disulfide-linked peptides in enzymatic (e.g., Lys-C) digests. The added Scrambled Disulfides function setting of BiopharmaLynx 1.3 makes it possible for identification of any potential disulfide linkages of a protein in an automated mode.

This integrated approach should be applicable for routine mapping and monitoring of disulfide linkages in mAbs and other therapeutic proteins with multiple disulfide linkages.

References

1. Gupta K, Kumar M, Balaram P. Disulfide bond assignments by mass 1. spectrometry of native natural peptides: cysteine pairing in disulfide bonded conotoxins. *Anal Chem* 2010; 82, 8313-8319.
2. Chumsae C, Gaza-Bulseco G, Liu H. Identification and localization of unpaired 2.cysteine residues in monoclonal antibodies by fluorescence labeling and massspectrometry. *Anal Chem* 2009; 81, 6449-6457.
3. Wen D, Wildes CP, Silvian L, Walus L, et al. Disulfide structure of the leucine-3.rich repeat C-terminal cap and C-terminal stalk region of Nogo-66 receptor. *Biochemistry* 2005; 44, 16491-16501.
4. Zhang W, Marzilli LA, Rouse JC, Czupryn MJ. Complete disulfide bond 4.assignment of a recombinant immunoglobulin G4 monoclonal antibody. *Anal Biochem* 2002; 311, 1-9.
5. Xie H, Chakraborty A, Ahn J, Yu YQ, et al. Rapid comparison of a candidate 5.biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies. *MAbs* 2010; 2, 379-394.
6. Silva JC, Denny R, Dorschel CA, Gorenstein, M, et al. Quantitative proteomic6.analysis by accurate mass

retention time pairs. *Anal Chem* 2005, 77, 2187-2200.

7. Xie H, Gilar M, Gebler JC. Characterization of protein impurities and site-specific modifications using peptide mapping with liquid chromatography and data independent acquisition mass spectrometry. *Anal Chem* 2009; 81, 5699-5708.
8. Xie H, Chen W, Gilar M, Skilton SJ, Mazzeo JR. Separation and Characterization of N-linked Glycopeptides on Hemagglutinins in a Recombinant Influenza Vaccine. *Waters Application Note* 2009; 720003173en.
9. Xie H, Chakraborty AB, Chen W. Towards Fast Mapping of Protein Disulfide Bonds: An Integrated Workflow for Automatic Assignment of Disulfide Pairing. Mass Spec 2010 (*Practical Applications of Mass Spectrometry in the Biotechnology Industry*), Marina Del Ray, CA, Sept. 8-10, 2010, P-107.
10. Wildgoose J, Campuzano I. SYNAPT G2 A Next-Generation, High-Resolution Time-of-Flight Mass Spectrometry Platform. *Waters Application Note* 2009; 720003027en.

Featured Products

[ACQUITY UPLC System <https://www.waters.com/514207>](https://www.waters.com/514207)

[MassLynx MS Software <https://www.waters.com/513662>](https://www.waters.com/513662)

[BiopharmaLynx <https://www.waters.com/513793>](https://www.waters.com/513793)

720003939, June 2011